Assessing the validity of QRISK3 in predicting cardiovascular events in systemic lupus erythematosus

ObjectivesTraditional cardiovascular risk calculators such as the Framingham Risk Score (FRS) have been shown to underestimate risk in patients with SLE. The QRISK3 calculator is unique in including SLE and corticosteroid use as risk factors. This study aims to assess the validity of QRISK3 compared...

Full description

Saved in:
Bibliographic Details
Published in:Lupus science & medicine 2022-02, Vol.9 (1), p.e000564
Main Authors: Zhu, Lisa, Singh, Manpreet, Lele, Sonia, Sahakian, Lori, Grossman, Jennifer, Hahn, Bevra, McMahon, Maureen
Format: Article
Language:English
Subjects:
Adult
Biomarkers
Cardiovascular disease
cardiovascular diseases
Cardiovascular Diseases - diagnosis
Cardiovascular Diseases - epidemiology
Cardiovascular Diseases - etiology
epidemiology
Epidemiology and Outcomes
High density lipoprotein
Humans
Lupus
lupus erythematosus
Lupus Erythematosus, Systemic - complications
Prospective Studies
Risk Assessment
Risk Factors
systemic
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ObjectivesTraditional cardiovascular risk calculators such as the Framingham Risk Score (FRS) have been shown to underestimate risk in patients with SLE. The QRISK3 calculator is unique in including SLE and corticosteroid use as risk factors. This study aims to assess the validity of QRISK3 compared with other cardiovascular risk models in a cohort of patients with SLE in the USA.MethodsWe studied a prospective cohort of 366 adult patients with SLE without history of any cardiovascular event and followed them for 10 years. We compared the diagnostic performance of QRISK3 with FRS, modified FRS, Atherosclerotic Cardiovascular Disease (ASCVD), and Predictors of Risk for Elevated Flares, Damage Progression and Increased Cardiovascular Disease in Patients with SLE (PREDICTS).ResultsSixty-four of the 366 patients (17.4%) experienced at least one cardiovascular event during the 10-year follow-up period. Of these patients 45% had a QRISK3 score >10%, whereas 20.5% of patients who did not have an event had a QRISK3 score >10% (p10%, FRS >10% and modified FRS >10%.ConclusionsBoth QRISK3 and PREDICTS demonstrated better performance in predicting risk of cardiovascular disease in this cohort of patients with SLE compared with FRS, modified FRS and ASCVD.
ISSN:2053-8790
2053-8790
DOI:10.1136/lupus-2021-000564